uncoupling protein 2Genealiases: BMIQ4 · SLC25A8 · UCPH
Q-omics provides the consensus-scored UCP2 profile across patient tissues and cancer cell-line models. UCP2 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, UCP2 is differentially expressed in 13, with the highest sampling consensus in STAD. Additionally, UCP2 RNA expression shows 16,054 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, STAD, and THYM as cancer lineages where UCP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UCP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UCP2 survival associations across molecular data types. UCP2 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UCP2 RNA expression–survival associations across cancer types. High UCP2 expression shows unfavorable associations in KIRP, COAD, LAML and LGG, but favorable associations in HNSC and CESC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for UCP2 RNA expression.
This table summarizes UCP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for UCP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UCP2 shows lower tumor expression in KICH and higher tumor expression in STAD, THCA, UCEC, BLCA and BRCA. The STAD box plot shows higher UCP2 RNA expression in tumor versus normal tissue (log2 FC = +1.624, t-test p < 0.001).
This table shows molecular features associated with UCP2 in patient tissues and cancer cell lines. In patient samples, UCP2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, UCP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
